CD4 and Autoimmunity: Other novel TNFR2 agonists are also being studied as potential therapeutic targets for treatment of autoimmunity and other inflammatory disorders and have been shown to expand highly suppressive CD4+Tregs capable of CD8+ T cell repression in vitro (41).